# Reduced immunogenicity of MYC amplified, metastatic prostate cancer

## TL;DR

This study finds that MYC amplification in metastatic prostate cancer is linked to worse survival and reduced immune response.

## Contribution

The study links MYC amplification in prostate cancer to reduced immunogenicity using genomics data.

## Key findings

- Increased MYC amplification is found in metastatic prostate cancer.
- MYC amplification correlates with worse progression-free survival and reduced immunogenicity.

## Abstract

Objectives: Through a genomics-based approach analyzing gene expression levels and adaptive immune receptor recombinations, we sought to determine whether MYC amplification was associated with a worse outcome and reduced immunogenicity.

Methods: MYC copy numbers and the presence of adaptive immune receptor (IR) recombination sequencing reads were quantified in genomics files representing prostate cancer samples.

Results: Our results showed that increased MYC amplification was found in metastatic stages of prostate cancer. Furthermore, increased MYC amplification was not only associated with worse progression-free survival but also with reduced immunogenicity in metastatic tumors, as determined by the recovery of a reduced numbers of adaptive IR recombination sequencing reads from tumor RNAseq and tumor whole genome sequence files.

Conclusions: MYC amplification is associated with reduced tumor immunogenicity as assessed by the recovery of IR recombination reads from prostate cancer genomics files.